Ruxolitinib Cream Improves Moderate Atopic Dermatitis After Prior Topical Treatment Failure

Key Clinical Summary:  

• In the phase 3 TRuE-AD4 trial, 70.0% of adults receiving 1.5% ruxolitinib cream achieved at least a 75% improvement in Eczema Area and Severity Index (EASI-75) scores at week 8, compared with 18.5% receiving vehicle.
• Ruxolitinib cream provided rapid itch relief, with significantly more patients achieving at least a 4-point improvement in itch severity by day 2 and differences in current itch relief observed as early as 15 minutes after the first application.
• Treatment was generally well tolerated, with no serious treatment-related adverse events, suggesting that ruxolitinib cream may offer an additional topical option before escalation to systemic therapy.

Adults with moderate atopic dermatitis (AD) who previously experienced an inadequate response, intolerance, or contraindication to topical corticosteroids and topical calcineurin inhibitors achieved significant improvements in disease severity, itch, and quality of life with 1.5% ruxolitinib cream, according to findings from the phase 3 TRuE-AD4 trial.

The findings suggest that ruxolitinib cream may provide an effective topical treatment option for patients who would otherwise be considered for systemic therapy, potentially expanding treatment choices for patients with persistent symptoms despite conventional topical treatment.

Clinical Efficacy After Previous Topical Treatment Failure

The randomized, vehicle-controlled TRuE-AD4 trial (NCT06238817) evaluated the efficacy and safety of twice-daily 1.5% ruxolitinib cream in adults with moderate AD who had an inadequate response, intolerance, or contraindication to both topical corticosteroids and topical calcineurin inhibitors within the previous 12 months.

The study enrolled 241 adults aged 18 years or older who had an Investigator's Global Assessment (IGA) score of 3, an EASI score greater than 7, an itch numerical rating scale (NRS) score of at least 4, and 10% to 20% affected body surface area.

Participants were randomized 2:1 to receive ruxolitinib cream or vehicle twice daily for 8 weeks. Mean age was 37.0 years, 54.4% were female, and mean baseline EASI and itch NRS scores were 12.6 and 7.4, respectively.

At week 8, significantly more patients receiving ruxolitinib cream achieved both coprimary efficacy end points compared with vehicle:

• EASI-75: 70.0% vs 18.5% (P < .0001)
• IGA treatment success: 61.3% vs 13.6% (P < .0001)

IGA treatment success was defined as achieving a score of 0 or 1, indicating clear or almost clear skin, with at least a 2-point improvement from baseline.
Substantial improvements in both measures were observed as early as week 2 and continued through week 8.

Additional efficacy analyses showed that 59.1% of patients receiving ruxolitinib cream achieved EASI-90, while 27.3% achieved EASI-100 at week 8.
Treatment benefits were consistent regardless of previous systemic therapy or phototherapy use and across baseline EASI severity categories.

Rapid Itch Relief and Improved Quality of Life

Ruxolitinib cream also demonstrated rapid and sustained improvements in itch, a major contributor to sleep disturbances and reduced quality of life among patients with AD.

By day 2, 29.8% of patients receiving ruxolitinib cream achieved at least a 4-point improvement in itch NRS scores, compared with 13.7% receiving vehicle (P = .0072).

The difference increased over the first week of treatment, with corresponding response rates of 35.1% vs 9.9% on day 3 and 51.2% vs 13.9% on day 7.
At week 8, 62.5% of patients receiving ruxolitinib cream achieved this level of itch improvement, compared with 19.8% receiving vehicle (P < .0001).
When investigators assessed current itch without a recall period, differences between treatment groups were evident as early as 15 minutes after the first application.

Patient-reported outcomes also favored ruxolitinib cream. At week 8, 39.7% of patients receiving active treatment achieved a Patient-Oriented Eczema Measure score of 0 to 2, indicating clear or almost clear disease, compared with 8.6% receiving vehicle.

Improvements in Dermatology Life Quality Index scores, sleep-related impairment, and sleep disturbance were also observed beginning at week 2 and continued through week 8.

Safety and Tolerability Findings

Ruxolitinib cream demonstrated a generally favorable safety profile during the 8-week treatment period.

Treatment-emergent adverse events occurred in 35.0% of patients receiving ruxolitinib cream and 35.8% receiving vehicle.

The most commonly reported adverse events with ruxolitinib cream were application-site acne (3.8%), upper respiratory tract infection (3.8%), and nasopharyngitis (3.1%).

No serious treatment-related adverse events were reported. Investigators also observed no major adverse cardiovascular events, malignancies, serious infections, or thromboses among patients receiving ruxolitinib cream during the study period.

Systemic exposure to ruxolitinib remained generally low, with median plasma concentrations at weeks 2 and 8 approximately 5-fold below the threshold associated with Janus kinase–mediated myelosuppression in laboratory assays. No clinically meaningful changes in hematologic parameters were observed.

However, the relatively short 8-week controlled period limits conclusions about longer-term safety.

Implications for Managed Care

The findings may have implications for treatment sequencing and formulary management in moderate AD, particularly among patients whose symptoms remain uncontrolled after conventional topical therapy.

Patients who do not respond adequately to topical corticosteroids or topical calcineurin inhibitors may be considered for systemic treatment, including biologics or oral therapies. The TRuE-AD4 findings suggest that ruxolitinib cream could provide an additional topical option for selected patients before systemic treatment is initiated.

For managed care organizations, an effective topical option could potentially influence treatment pathways, systemic therapy utilization, and overall treatment expenditures. However, the trial did not directly evaluate health care resource utilization, cost-effectiveness, or rates of subsequent escalation to systemic therapy.

The investigators also noted that treatment selection may depend on patient preferences, safety considerations, and treatment costs.

Although the study demonstrated substantial improvements in clinical and patient-reported outcomes, its vehicle-controlled design did not establish comparative effectiveness against other active treatments. Longer-term research will be necessary to determine whether these improvements are sustained and whether ruxolitinib cream can reduce the need for systemic therapy in routine clinical practice.

Conclusion

In adults with moderate AD who previously experienced inadequate response, intolerance, or contraindication to topical corticosteroids and topical calcineurin inhibitors, 1.5% ruxolitinib cream significantly improved clinical disease severity, rapidly reduced itch, and improved patient-reported quality of life over 8 weeks.

The findings support ruxolitinib cream as a potential topical treatment option before escalation to systemic therapy, although additional evidence is needed to establish its long-term effectiveness, safety, and economic impact.

Reference

Carrascosa JM, Prajapati VH, Hong HC, et al. Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial. J Eur Acad Dermatol Venereol. 2026. doi:10.1111/jdv.70595